Multiple Sclerosis Journal · 2023 · 12 citations · 27 references
MedicineImmunologyPharmacotherapyImmunizationImmunopharmacologyImmunotherapyAdaptive Immune ModulationAdaptive Immune ResponsesAdverse Events Following ImmunizationImmune Response To VaccinationVaccinationVaccine EfficacyAntibodiesB Cell Response InductionFingolimod TherapySphingosine 1-Phosphate Receptor ModulationSphingosine 1-Phosphate Receptor Modulator TherapySphingosine 1-Phosphate Receptor ModulatorsVaccine-induced Antibody ResponsesVaccine-induced T-cell Responses
BACKGROUND: Sphingosine 1-phosphat receptor modulators (S1PRMs) have been linked to attenuated immune response to SARS-CoV-2 vaccines. OBJECTIVE: To characterize differences in the immune response to SARS-CoV-2 vaccines in patients on selective versus unselective S1PRMs. METHODS: Monocentric, longitudinal study on people with multiple sclerosis (pwMS) on fingolimod (FTY), siponimod (SIP), ozanimod (OZA), or without disease-modifying therapy (DMT) following primary and booster SARS-CoV-2 vaccination. Anti-SARS-CoV-2 antibodies and T-cell response was measured with electro-chemiluminescent immunoassay and interferon-γ release assay. RESULTS: Primary vaccination induced a significant antibody response in pwMS without DMT while S1PRM patients exhibited reduced antibody titers. The lowest antibodies were found in patients on FTY, whereas patients on OZA and SIP presented significantly higher levels. Booster vaccinations induced increased antibody levels in untreated patients and comparable titers in patients on OZA and SIP, but no increase in FTY-treated patients. While untreated pwMS developed a T-cell response, patients on S1PRMs presented a diminished/absent response. Patients undergoing SARS-CoV-2 vaccination before onset of S1PRMs presented a preserved, although attenuated humoral response, while T-cellular response was blunted. CONCLUSION: Our data confirm differential effects of selective versus unselective S1PRMs on T- and B-cell response to SARS-CoV-2 vaccination and suggest association with S1PRM selectivity rather than lymphocyte redistribution.
27
The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors
Volker Brinkmann, Michael D. Davis, Christopher E. Heise et al. · Journal of Biological Chemistry · 2002 · 1.5K citations · Full text
Medicine, Immunology, Pharmacology +17
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Shuo Feng, Daniel J. Phillips, Thomas White et al. · Nature Medicine · 2021 · 1.2K citations · Full text
Fiona L. Scott, Bryan Clemons, Jennifer L. Brooks et al. · British Journal of Pharmacology · 2016 · 305 citations · Full text